JPMorgan Chase & Co. Increases Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target to $39.00

Mirum Pharmaceuticals (NASDAQ:MIRMGet Free Report) had its price objective raised by equities research analysts at JPMorgan Chase & Co. from $31.00 to $39.00 in a report released on Tuesday, Benzinga reports. The brokerage presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price objective would indicate a potential upside of 23.30% from the company’s previous close.

Several other research firms have also issued reports on MIRM. SVB Leerink dropped their price target on shares of Mirum Pharmaceuticals from $44.00 to $43.00 and set an “outperform” rating on the stock in a research report on Monday, March 18th. Morgan Stanley upped their price target on shares of Mirum Pharmaceuticals from $53.00 to $57.00 and gave the stock an “overweight” rating in a research report on Tuesday. Stifel Nicolaus reaffirmed a “buy” rating and set a $48.00 price target on shares of Mirum Pharmaceuticals in a research report on Monday. HC Wainwright upped their price target on shares of Mirum Pharmaceuticals from $58.00 to $66.00 and gave the stock a “buy” rating in a research report on Monday. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $40.00 price target on shares of Mirum Pharmaceuticals in a research report on Thursday, May 9th. Ten investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $53.64.

Check Out Our Latest Report on MIRM

Mirum Pharmaceuticals Stock Down 4.2 %

MIRM traded down $1.37 during trading on Tuesday, reaching $31.63. The company had a trading volume of 369,635 shares, compared to its average volume of 564,124. The business’s fifty day moving average price is $25.26 and its 200 day moving average price is $27.25. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.68 and a quick ratio of 3.47. The company has a market cap of $1.49 billion, a P/E ratio of -8.53 and a beta of 1.10. Mirum Pharmaceuticals has a 12 month low of $23.14 and a 12 month high of $35.56.

Mirum Pharmaceuticals (NASDAQ:MIRMGet Free Report) last announced its quarterly earnings data on Wednesday, May 8th. The company reported ($0.54) EPS for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.14). The business had revenue of $69.22 million during the quarter, compared to the consensus estimate of $69.71 million. Mirum Pharmaceuticals had a negative return on equity of 56.46% and a negative net margin of 69.67%. Equities analysts anticipate that Mirum Pharmaceuticals will post -1.39 EPS for the current year.

Insider Activity at Mirum Pharmaceuticals

In related news, Director Saira Ramasastry sold 5,000 shares of the company’s stock in a transaction dated Wednesday, June 5th. The shares were sold at an average price of $25.68, for a total value of $128,400.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In related news, Director Saira Ramasastry sold 5,000 shares of the company’s stock in a transaction dated Wednesday, June 5th. The shares were sold at an average price of $25.68, for a total transaction of $128,400.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, COO Peter Radovich sold 4,303 shares of the company’s stock in a transaction dated Monday, March 25th. The stock was sold at an average price of $25.80, for a total transaction of $111,017.40. Following the sale, the chief operating officer now directly owns 29,013 shares of the company’s stock, valued at approximately $748,535.40. The disclosure for this sale can be found here. 22.87% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Mirum Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the company. Swiss National Bank lifted its position in Mirum Pharmaceuticals by 1.3% during the third quarter. Swiss National Bank now owns 54,400 shares of the company’s stock worth $1,719,000 after purchasing an additional 700 shares during the period. New York State Common Retirement Fund boosted its stake in shares of Mirum Pharmaceuticals by 0.4% in the 4th quarter. New York State Common Retirement Fund now owns 222,864 shares of the company’s stock valued at $6,579,000 after purchasing an additional 918 shares in the last quarter. Janney Montgomery Scott LLC boosted its stake in shares of Mirum Pharmaceuticals by 5.3% in the 3rd quarter. Janney Montgomery Scott LLC now owns 18,925 shares of the company’s stock valued at $598,000 after purchasing an additional 950 shares in the last quarter. Golden State Equity Partners boosted its stake in shares of Mirum Pharmaceuticals by 5.3% in the 4th quarter. Golden State Equity Partners now owns 18,930 shares of the company’s stock valued at $559,000 after purchasing an additional 950 shares in the last quarter. Finally, Wetzel Investment Advisors Inc. boosted its stake in shares of Mirum Pharmaceuticals by 71.4% in the 1st quarter. Wetzel Investment Advisors Inc. now owns 2,400 shares of the company’s stock valued at $57,000 after purchasing an additional 1,000 shares in the last quarter.

About Mirum Pharmaceuticals

(Get Free Report)

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.

Read More

Analyst Recommendations for Mirum Pharmaceuticals (NASDAQ:MIRM)

Receive News & Ratings for Mirum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.